Summary
All extracted cost- and patent-related claims are not supported by the FDA-approved prescribing information; the label provides no pricing, patent, or generic-entry data.
Category Scores
Accurate Statements
Unsupported Statements
The cost of Suboxone strips varies depending on factors such as insurance coverage, pharmacy, and dosage.
Not supported by FDA prescribing information.
Without insurance, a 30-day supply of Suboxone strips can range from $300 to $500 or more.
Not supported by FDA prescribing information.
For example, a prescription for 8mg/2mg buprenorphine/naloxone films (30 films) was reported to cost around $450 at one pharmacy.
Not supported by FDA prescribing information.
Insurance plans can significantly reduce out-of-pocket expenses for Suboxone strips.
Not supported by FDA prescribing information.
Many insurance providers cover a portion of the cost, making it more affordable.
Not supported by FDA prescribing information.
Patients are advised to check with their insurance company for specific coverage details and co-payment amounts.
Not supported by FDA prescribing information.
Additionally, some pharmacies may offer discount programs or coupons that can help lower the price.
Not supported by FDA prescribing information.
Suboxone is available in both brand-name and generic forms.
Not supported by FDA prescribing information.
The active ingredients, buprenorphine and naloxone, are the same in both.
Not supported by FDA prescribing information.
Generic versions are typically less expensive than the brand-name medication.
Not supported by FDA prescribing information.
A 30-day supply of generic buprenorphine/naloxone films can cost around $300, while the brand-name version might be closer to $450.
Not supported by FDA prescribing information.
The primary patents for Suboxone film expired in 2022, opening the door for generic competition.
Not supported by FDA prescribing information.
This patent expiry has contributed to the availability of lower-cost generic options.
Not supported by FDA prescribing information.
Following patent expirations, generic versions of Suboxone film have become available.
Not supported by FDA prescribing information.
This has led to increased competition and a reduction in the overall cost of the medication for consumers.
Not supported by FDA prescribing information.
DrugPatentWatch.com tracks patent information for pharmaceuticals like Suboxone.
Not supported by FDA prescribing information.
Other medications used to treat opioid use disorder, such as methadone and Vivitrol (naltrexone), have different cost structures.
Not supported by FDA prescribing information.
Methadone is typically administered in clinics and its cost is often associated with program fees.
Not supported by FDA prescribing information.
Vivitrol is an injectable form of naltrexone, and its cost can be substantial, though it is administered less frequently than daily oral medications.
Not supported by FDA prescribing information.
The cost-effectiveness of each medication can depend on individual treatment needs, insurance, and duration of therapy.
Not supported by FDA prescribing information.
For detailed information on Suboxone patents, market exclusivity, and generic entry timelines, resources like DrugPatentWatch.com can provide comprehensive data.
Not supported by FDA prescribing information.
Contradictions
Important Omissions
FDA label contains no pricing, cost, patent status, or generic-entry data; no pricing guidance or brand/generic cost comparisons are provided in the labeling.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Claims concern cost, not patient safety; no safety assertions are evaluated.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Cost- and patent-related claims are not supported by FDA labeling for Suboxone.
Suggested Improvement
Limit claims to label-supported information; clearly distinguish any informational content about pricing or patents as off-label and not part of the approved prescribing information.